α1アンチトリプシン欠乏症治療の世界市場規模：治療モダリティ別、診断テスト別、流通チャネル別、地域別、範囲および予測

α1アンチトリプシン欠乏症治療の市場規模と予測

α1アンチトリプシン欠乏症治療市場規模は、2023年に18億2,000万米ドルと評価され、2024年から2031年にかけてCAGR 9.41%で成長し、2031年には35億米ドルに達すると予測されています。α1アンチトリプシン欠乏症（AATD）は、遺伝性慢性閉塞性肺疾患（COPD）としても知られ、肺および関連疾患に対する感受性を著しく高める遺伝性疾患です。この疾患は、両親からα1アンチトリプシン（AAT）遺伝子の正常コピーと損傷コピーのどちらか一方、または2つの損傷コピーを受け継いだ場合に発症します。この遺伝的欠損を持つ人は、酵素活性による損傷から肺を守るために不可欠な蛋白質であるα-1アンチトリプシンを十分なレベルで産生する能力が低下します。その結果、COPDを含む重篤な肺疾患を発症しやすくなります。α-1アンチトリプシン欠乏症の治療の重要性は、各国の政府によるガイドラインや勧告に後押しされ、大きな注目を集めています。

これらのガイドラインは、この遺伝性疾患が罹患者の健康に与える影響を軽減するために、早期診断と適切な管理戦略の必要性を強調しています。

α1アンチトリプシン欠乏症治療の世界市場力学

世界のα1アンチトリプシン欠乏症治療市場を形成している主な市場力学

主な市場促進要因

市場成長を加速させる研究開発活動の活発化

α1アンチトリプシン欠乏症（AATD）治療市場は、研究開発（R&D）活動の活発化により、大きな成長を遂げようとしています。官民の戦略的な協力関係により、継続的な技術革新のための強固な環境が醸成されています。こうした協力関係は、AATDの治療を目的とした新薬や先進医療技術の開発において極めて重要です。

ヘルスケア・インフラ投資の増加

ヘルスケア・インフラへの投資も、AATD治療市場の成長を促す重要な要因のひとつです。ヘルスケア支出の増加は、特に発展途上国におけるインフラ整備を促進しています。このような拡大は、新しく先進的な医療技術、機器、医薬品の導入と展開をサポートし、AATD治療への需要を直接後押ししています。AATDの診断と治療に関するガイドラインの出現、潜在的なパイプライン製品の開発、AATDに対する意識の高まりが、AATD治療薬の需要を押し上げています。AATDの有病率の増加は、予測期間中の市場の成長見通しをさらに高めると予想されます。

患者支援団体の役割

患者支援団体や支援組織は、AATD治療において重要な役割を果たしています。これらの団体は、認知度を高め、研究資金を確保し、AATD患者の治療選択肢へのアクセス改善を提唱しています。彼らの努力はヘルスケア政策や意思決定プロセスに大きな影響を与え、市場拡大にプラスに寄与しています。患者を支援する環境を醸成し、政策変更を推進することで、こうしたアドボカシー団体はAATD患者のニーズを確実に満たし、市場の成長をさらに加速させる。

遺伝子検査の普及：

遺伝子検査、血液検査、生検検査の普及が進んでいることが、市場の成長に大きく寄与しています。α1アンチトリプシン欠乏症（AATD）に対する認識を高めることを目的とした公的および民間部門の取り組みも、極めて重要な役割を果たしています。このような努力は、大手メーカーが確立した組織化された流通網によって強化され、新しい治療が効率的に患者に届くことを保証しています。効果的な治療薬に対する需要の高まりと早期診断法の利用拡大は、市場の成長軌道にプラスの影響を与えています。

主な課題

研究開発費の高騰：

研究開発に伴う多額の費用は、市場の成長にとって最も大きな制約のひとつです。新しい治療法や医療技術を開発するための経済的負担は、特に中小企業や十分な資金を持たない発展途上国にとっては、進展を妨げる要因となります。

認識とインフラの欠如：

多くの発展途上国や低開発諸国では、α1アンチトリプシン欠乏症（AATD）を効果的に診断・治療するための認識と必要なインフラの両方が著しく不足しています。このような知識や資源の不足は診断率の低迷を招き、市場拡大の妨げとなっています。

遅々として進まない医薬品承認と特許切れ：

新薬や阻害剤の承認プロセスが遅いことも市場の課題です。さらに、血漿分画の能力が限られていることや、特許切れの件数が増加していることも障害となり、新たな治療法の登場を遅らせています。

多彩な症状による過小診断：

認知度が高まっているにもかかわらず、AATDは臨床症状が多様であり、標準的なスクリーニング方法が存在しないため、依然として診断が不十分です。この診断不足は、一般市民とヘルスケア専門家の双方の認識不足によって悪化し、診断と治療の遅れにつながり、市場成長の妨げとなっています。

限られた治療選択肢：

治療法の開発は進んでいるもの、特に重症の患者や既存の治療法に反応しない患者にとって、利用可能な治療選択肢はまだ比較的少ないです。このように、特定の疾患経路をターゲットとする有効な医薬品が乏しいため、多くの患者の医療ニーズが満たされておらず、市場の成長が制限されています。

複雑な病態生理：

AATDは遺伝的、環境的、免疫学的要因が複雑に絡み合っているため、最適な安全性と有効性を有する標的治療薬の開発が困難です。この疾患の根本的なメカニズムを理解し、適切な治療標的を特定するためには広範な研究が必要であり、これが新たな治療法の開発と商業化を遅らせています。

ヘルスケアインフラの格差：

ヘルスケアインフラの格差、特に資源に乏しい地域や十分なサービスを受けていないコミュニティにおける格差は、患者が診断検査や専門的治療を受けることを制限しています。不十分なヘルスケア施設、訓練を受けた人材の不足、遠隔地へ治療を届けるための物流の課題などがこうした抑制要因となり、患者の治療へのアクセスやアドヒアランスを妨げています。

主要動向

意識の高まり：

α1アンチトリプシン欠乏症（AATD）に対する一般市民と医療従事者の意識は著しく高まっています。こうした意識の高まりにより、早期診断と迅速な治療開始が促進されています。その結果、治療を必要とする患者層が拡大し、AATD治療薬の需要を牽引しています。

診断ツールの拡大：

技術の進歩により、AATDのより正確で利用しやすい診断ツールの開発が進んでいます。このようなツールの改善により、早期発見・早期介入が可能となり、AATDの効果的な管理と合併症の予防に極めて重要です。

テレヘルスの役割の増大：

遠隔医療プラットフォームは、AATDの管理においてますます重要な役割を果たしています。これらのプラットフォームは、専門医、サポートグループ、教育リソースへの患者のアクセスを向上させる。遠隔医療は、特に遠隔地や十分なサービスを受けていない地域の患者にとって、継続的なケアとサポートを容易にします。

個別化医療の台頭：

個別化医療の動向は、AATDの治療においても顕著になってきています。個々の患者の特徴、遺伝子プロファイル、疾患の重症度に基づいて治療計画を調整することが、より効果的であることが証明されつつあります。個別化医療のアプローチにより、患者はそれぞれの病態に最も適切で効果的な治療を受けることができます。

新興市場への注目の高まり：

発展途上国における医療インフラの整備と可処分所得の増加は、AATD治療プロバイダーにとって新たな機会となります。これらの市場が拡大するにつれて、AATD治療に対する需要が大きく伸びる可能性があります。こうした新興市場をターゲットとする企業も増えており、参入の幅を広げ、市場への浸透を図っています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 α1アンチトリプシン欠乏症治療市場：治療モダリティ別

• 増強療法
• 気管支拡張薬と副腎皮質ステロイド薬
• 遺伝子治療
• 支持療法

第5章 α1アンチトリプシン欠乏症治療市場：診断テスト別

• 血清学的検査
• 遺伝子検査
• 画像検査

第6章 α1アンチトリプシン欠乏症治療市場：流通チャネル別

• 病院
• 専門クリニック
• 小売薬局

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Takeda Pharmaceutical Company Limited
• Alexion Pharmaceuticals Inc.
• Chiesi Farmaceutici S.p.A.
• Vertex Pharmaceuticals Incorporated
• Boehringer Ingelheim GmbH
• United Therapeutics Corporation
• Paramount Biosciences Inc.
• Protalix BioTherapeutics Inc.
• Galecto Inc.

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Alpha 1 Antitrypsin Deficiency Treatment Market Size And Forecast

Alpha 1 Antitrypsin Deficiency Treatment Market size was valued at USD 1.82 Billion in 2023 and is projected to reach USD 3.5 Billion by 2031, growing at a CAGR of 9.41% from 2024 to 2031. Alpha-1 Antitrypsin Deficiency (AATD), also known as genetic Chronic Obstructive Pulmonary Disease (COPD), is a hereditary condition that significantly increases susceptibility to lung and related diseases. This condition arises when an individual inherits either one normal and one damaged copy or two damaged copies of the alpha-1 antitrypsin (AAT) gene, which is received from each parent. Those with this genetic deficiency have a reduced ability to produce sufficient levels of alpha-1 antitrypsin, a protein essential for protecting the lungs from damage caused by enzyme activity. As a result, they are more prone to developing severe lung conditions, including COPD. The importance of treating alpha-1 antitrypsin deficiency has garnered considerable attention, driven by the guidelines and recommendations provided by governments across various countries.

These guidelines emphasize the need for early diagnosis and appropriate management strategies to mitigate the impact of this genetic disorder on affected individuals' health.

Global Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics

The key market dynamics that are shaping the global alpha 1 antitrypsin deficiency treatment market include:

Key Market Drivers

Increasing Research and Development Activities to Accelerate Market Growth

: The alpha-1 antitrypsin deficiency (AATD) treatment market is poised for significant growth, driven by an upsurge in research and development (R&D) activities. Strategic collaborations between public and private entities are fostering a robust environment for continuous innovation. These collaborations are crucial in the development of new pharmaceuticals and advanced medical technologies aimed at treating AATD.

Increasing Healthcare Infrastructure Investment

: Investment in healthcare infrastructure is another critical factor driving the growth of the AATD treatment market. Increased healthcare spending is facilitating infrastructure improvements, particularly in developing countries. This expansion supports the adoption and deployment of new and advanced medical technologies, equipment, and pharmaceuticals, directly boosting the demand for AATD therapies. The emerging guidelines for the diagnosis and treatment of the condition, the development of potential pipeline products, and rising awareness about AATD. The increasing prevalence of AATD is expected to further enhance the market's growth prospects during the forecast period.

Role of Patient Advocacy Groups

: Patient advocacy groups and support organizations play a crucial role in the AATD treatment landscape. These groups are instrumental in raising awareness, securing funding for research, and advocating for improved access to treatment options for individuals with AATD. Their efforts significantly influence healthcare policies and decision-making processes, contributing positively to market expansion. By fostering a supportive environment for patients and driving policy changes, these advocacy groups ensure that the needs of those with AATD are met, further accelerating market growth.

Increasing Prevalence of Genetic Testing:

The increasing prevalence of genetic testing, blood tests, and biopsy tests is significantly contributing to the market's growth. Public and private sector initiatives aimed at raising awareness about Alpha-1 Antitrypsin Deficiency (AATD) are also playing a pivotal role. These efforts are bolstered by a well-organized distribution network established by leading manufacturers, ensuring that new treatments reach patients efficiently. The growing demand for effective medications and the expanding use of early diagnostic methods are positively impacting the market's growth trajectory.

Key Challenges

High R&D Costs:

The significant expenses associated with research and development pose one of the most substantial limitations to the market's growth. The financial burden of developing new treatments and medical technologies can stymie progress, particularly for smaller companies and developing nations lacking adequate funding.

Lack of Awareness and Infrastructure:

In many developing and underdeveloped countries, there is a notable deficiency in both the awareness and the necessary infrastructure to effectively diagnose and treat Alpha-1 Antitrypsin Deficiency (AATD). This lack of knowledge and resources leads to sluggish diagnostic rates, further hampering market expansion.

Slow Medication Approval and Patent Expirations:

The market is also challenged by the slow approval process for new medications and inhibitors. Additionally, the limited capacity for plasma fractionation and the increasing number of patent expirations present further obstacles, delaying the availability of new treatments.

Underdiagnosis Due to Variable Presentation:

Despite growing awareness, AATD remains underdiagnosed because of its variable clinical presentation and the absence of standard screening procedures. This underdiagnosis, exacerbated by a lack of awareness among both the general public and healthcare professionals, results in delayed diagnosis and treatment, hindering market growth.

Limited Treatment Options:

Although advancements in therapeutic development have been made, there are still relatively few treatment options available, particularly for patients with severe forms of the disease or those who do not respond well to existing treatments. This scarcity of effective medicines targeting specific disease pathways leaves many patients' medical needs unmet, restricting market growth.

Complex Disease Pathophysiology:

AATD involves a complex interplay of genetic, environmental, and immunological factors, making it challenging to develop targeted therapies with optimal safety and efficacy profiles. Extensive research is needed to understand the disease's underlying mechanisms and identify suitable therapeutic targets, which delays the development and commercialization of new treatments.

Healthcare Infrastructure Disparities:

Disparities in healthcare infrastructure, especially in resource-constrained regions and underserved communities, limit patients' access to diagnostic tests and specialized care. Inadequate healthcare facilities, a shortage of trained personnel, and logistical challenges in delivering treatments to remote areas contribute to these constraints, impeding patient access and adherence to therapy.

Key Trends

Growing Awareness:

There is a significant increase in both public and healthcare professional awareness regarding Alpha-1 Antitrypsin Deficiency (AATD). This heightened awareness is facilitating earlier diagnosis and prompt initiation of treatment. As a result, the patient pool requiring treatment is expanding, driving demand for AATD therapies.

Expanding Diagnostic Tools:

Technological advancements are leading to the development of more accurate and accessible diagnostic tools for AATD. These improved tools enable earlier identification and intervention, which is crucial for managing the disease effectively and preventing complications.

Growing Role of Telehealth:

Telehealth platforms are playing an increasingly important role in the management of AATD. These platforms improve patient access to specialists, support groups, and educational resources. Telehealth facilitates continuous care and support, especially for patients in remote or underserved areas.

Rise of Personalized Medicine:

The trend towards personalized medicine is becoming more prominent in the treatment of AATD. Tailoring treatment plans based on individual patient characteristics, genetic profiles, and disease severity is proving to be more effective. Personalized medicine approaches ensure that patients receive the most appropriate and effective therapies for their specific conditions.

Increased Focus on Emerging Markets:

The growing healthcare infrastructure and rising disposable incomes in developing countries present new opportunities for AATD treatment providers. As these markets expand, there is potential for significant growth in the demand for AATD therapies. Companies are increasingly targeting these emerging markets to broaden their reach and enhance market penetration.

Global Alpha 1 Antitrypsin Deficiency Treatment Market Regional Analysis

Here is a more detailed regional analysis of the global alpha 1 antitrypsin deficiency treatment market:

Asia Pacific

The Asia-Pacific region significantly dominates the global alpha-1 antitrypsin deficiency (AATD) treatment market. This dominance is due to its vast patient population and an expanding elderly demographic.

This region is expected to experience substantial growth due to several key factors. The burgeoning medical tourism industry in Asia-Pacific, spurred by the availability of advanced medical treatments at competitive prices, is attracting patients globally. This influx boosts the demand for sophisticated healthcare services, including AATD treatments.

Rising healthcare expenditure across Asia-Pacific countries is also contributing to market growth. Increased investment in healthcare infrastructure and services reflects a broader commitment to enhancing medical care and accessibility.

In addition, regional governments are prioritizing the development of healthcare infrastructure, with significant initiatives aimed at advancing the biotechnology, agriculture, and pharmacology sectors.

These initiatives not only improve the overall healthcare landscape but also promote the development and availability of advanced AATD therapies, further driving market expansion in the region.

North America

North America is anticipated to witness the fastest growth in the global alpha-1 antitrypsin deficiency (AATD) treatment market during the forecast period.

This rapid growth is primarily driven by several factors, including the increasing number of clinical trials focused on genetic disease therapeutics.

These trials are pivotal in advancing treatment options and improving patient outcomes, thereby solidifying the region's leadership in the market.

The region benefits from a well-established healthcare infrastructure, characterized by the availability of qualified specialists and advanced genetic testing equipment. These resources collectively facilitate superior diagnosis and treatment of AATD, ensuring that patients receive timely and accurate care.

The presence of cutting-edge medical facilities and a robust healthcare system further enhances the region's capability to manage AATD effectively.

High healthcare spending and favorable reimbursement policies are additional factors that support the market's growth in North America. These financial aspects make it easier for patients to access necessary treatments without facing prohibitive costs.

Insurance coverage and reimbursement plans also incentivize healthcare providers to adopt and recommend advanced AATD therapies, thereby increasing the overall treatment rate.

Significant investments by major players in the region are fueling research and development activities, leading to improved diagnostics and a higher rate of identification of AATD cases. These investments are crucial in driving innovation and the development of new, more effective treatments.

Pharmaceutical companies and biotech firms are actively engaged in exploring novel therapies, including gene therapies and advanced augmentation therapies, which hold promise for better management of AATD.

Furthermore, the rising prevalence of respiratory disorders in North America contributes to the market's substantial share. As respiratory conditions often exacerbate the symptoms of AATD, there is a growing need for effective treatment solutions.

The increasing incidence of conditions such as Chronic Obstructive Pulmonary Disease (COPD) highlights the importance of addressing AATD comprehensively.

Europe

Europe is anticipated to show lucrative growth in the global alpha 1 antitrypsin deficiency treatment market during the forecast period.

Increasing research and development initiatives aimed at enhancing treatment for various respiratory disorders.

Growing consumer awareness about AATD and its therapeutic options is driving demand. Furthermore, the rise in the elderly population, more susceptible to respiratory diseases, is positively influencing the market dynamics.

Europe's focus on improving healthcare services and its commitment to addressing respiratory health issues make it a key player in the global AATD treatment market.

Europe holds the position of the second-largest market for the alpha-1 antitrypsin deficiency (AATD) industry, attributed to its abundance of qualified specialists and access to modern genetic testing equipment. This well-established infrastructure facilitates early and accurate diagnosis, leading to effective management and treatment of AATD.

Looking ahead, Europe is poised for rapid development and is expected to grow at the fastest rate throughout the forecast period.

The expanding patient pool, due in part to better diagnostic capabilities and increasing awareness of AATD, is contributing significantly to market expansion.

In Addition, the region benefits from robust government backing, with numerous initiatives aimed at improving healthcare infrastructure and supporting research and development in genetic and respiratory disorders.

Government policies and funding are playing a crucial role in advancing the AATD market in Europe. These measures include support for public health campaigns to raise awareness about AATD, investments in state-of-the-art medical facilities, and incentives for pharmaceutical companies to develop innovative treatments.

Furthermore, collaborations between the public and private sectors are enhancing research efforts, leading to the development of new and more effective therapies.

The growing geriatric population in Europe, which is more prone to respiratory conditions, also fuels the demand for AATD treatments. As a result, the region is witnessing an increase in the adoption of advanced medical technologies and therapies designed to improve patient outcomes.

With these favorable conditions, Europe is set to solidify its position as a key player in the global AATD treatment market, driving significant advancements and improvements in patient care.

Global Alpha 1 Antitrypsin Deficiency Treatment Market Segmentation Analysis

The Global Alpha 1 Antitrypsin Deficiency Treatment Market is segmented based on Therapeutic Modality, Diagnostics Test, Distribution Channel, And Geography.

Alpha 1 Antitrypsin Deficiency Treatment Market, By Therapeutic Modality

• Augmentation Therapy
• Bronchodilators Corticosteroids
• Gene Therapy
• Supportive Care

Based on Therapeutic Modality, the Global Alpha 1 Antitrypsin Deficiency Treatment Market is bifurcated into Augmentation Therapy, Bronchodilators Corticosteroids, Gene Therapy, and Supportive Care. Bronchodilators Corticosteroids segment showing significant growth in the global alpha 1 antitrypsin deficiency treatment market. The rise of the corticosteroid segment in the alpha-1 antitrypsin deficiency (AATD) market is primarily driven by the increasing prevalence of chronic illnesses, an aging population, and heightened Research and Development (R&D) spending. The global burden of chronic diseases is anticipated to escalate significantly in the coming years, further fueling the demand for corticosteroid therapies.

Alpha 1 Antitrypsin Deficiency Treatment Market, By Diagnostics Tests

• Serological Tests
• Genetic Testing
• Imaging Studies

Based on Diagnostics Tests, the Global Alpha 1 Antitrypsin Deficiency Treatment Market is bifurcated into Serological Tests, Genetic Testing, and Imaging Studies. The genetic testing segment showing significant growth in the global alpha 1 antitrypsin deficiency treatment market owing to the accurate diagnosis of alpha-1 antitrypsin deficiency (AATD) is crucial as it ensures reliable identification of the condition, providing a definitive diagnosis. This precision extends to carrier identification, helping to detect individuals who carry the AATD gene but may not yet exhibit symptoms. Such early detection facilitates genetic counseling and intervention for potential offspring. Moreover, timely and accurate diagnosis allows for the early initiation of treatment, which can greatly enhance patient outcomes and improve the overall management of the disease.

Alpha 1 Antitrypsin Deficiency Treatment Market, By Distribution Channel

• Hospitals
• Specialty Clinics
• Retail Pharmacies

Based on the Distribution Channel, the Global Alpha 1 Antitrypsin Deficiency Treatment Market is bifurcated into Hospitals, Specialty Clinics, and Retail Pharmacies. The hospital segment showing significant growth in the global alpha 1 antitrypsin deficiency treatment market driven by the increasing patient preference for hospital admissions for treatment. The desire for comprehensive care and access to advanced medical resources. Additionally, the presence of highly skilled medical personnel enhances the quality of treatment, contributing to a growing market share in the coming years.

Alpha 1 Antitrypsin Deficiency Treatment Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Alpha 1 Antitrypsin Deficiency Treatment Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. The Asia-Pacific region significantly dominates the global alpha-1 antitrypsin deficiency (AATD) treatment market. The vast patient population and an expanding elderly demographic are the reason likely to enable the region hold major share in the market. This region is expected to experience substantial growth due to several key factors. The burgeoning medical tourism industry in Asia-Pacific, spurred by the availability of advanced medical treatments at competitive prices, is attracting patients globally. This influx boosts the demand for sophisticated healthcare services, including AATD treatments. Rising healthcare expenditure across Asia-Pacific countries is also contributing to market growth. Increased investment in healthcare infrastructure and services reflects a broader commitment to enhancing medical care and accessibility.

Key Players

• The "Global Alpha 1 Antitrypsin Deficiency Treatment Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as
• Takeda Pharmaceutical Company Limited, Alexion Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals Incorporated, Boehringer Ingelheim GmbH, United Therapeutics Corporation, Paramount Biosciences Inc., Protalix BioTherapeutics, Inc., Galecto, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Global Alpha 1 Antitrypsin Deficiency Treatment Market Recent Developments
• In October 2022, Kamada Ltd., a vertically integrated global biopharmaceutical company focused on specialty plasma-derived therapeutics, announced that it had been awarded a three-year extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM(R), HEPAGAM(R), VARIZIG(R), and WINRHO(R) SDF, for an estimated total value of US$ 22 million. This award ensures that such things will continue to be offered on the Canadian market.
• In May 2022, Boehringer Ingelheim announced that ArisGlobal had bought their digital invention, BRASS. This data insights engine will be integrated into ArisGlobal's LifeSphere(R) technology platform as LifeSphere Clarity, and it will play an important role in driving industry-wide improvement in pharmacovigilance and patient safety.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Alpha 1 Antitrypsin Deficiency Treatment Market, By Therapeutic Modality

• Augmentation Therapy
• Bronchodilators and Corticosteroids
• Gene Therapy
• Supportive Care

5. Alpha 1 Antitrypsin Deficiency Treatment Market, By Diagnostic Tests

• Serological Tests
• Genetic Testing
• Imaging Studies

6. Alpha 1 Antitrypsin Deficiency Treatment Market, By Distribution Channel

• Hospitals
• Specialty Clinics
• Retail Pharmacies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Takeda Pharmaceutical Company Limited
• Alexion Pharmaceuticals Inc.
• Chiesi Farmaceutici S.p.A.
• Vertex Pharmaceuticals Incorporated
• Boehringer Ingelheim GmbH
• United Therapeutics Corporation
• Paramount Biosciences Inc.
• Protalix BioTherapeutics Inc.
• Galecto Inc.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References